Status:
UNKNOWN
Predicting the Progression to Chronic Fibrosis of Lung Lesions Related to Covid-19 Infection From Chest CT Images
Lead Sponsor:
Centre Chirurgical Marie Lannelongue
Conditions:
CoV2 SARS Pneumonia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The main differences observed between SARSCoV-2 pneumonia and other epidemic viral pneumopathies (e.g., seasonal influenza) are the greater infectivity of SARSCoV-2, the clinical severity of the disea...
Eligibility Criteria
Inclusion
- Patient hospitalized for SARS CoV-2 infection proved by RT-PCR and/or by a typical SARS CoV-2 pneumonia clinic and imaging that required hospitalization Scan performed when the patient is no longer oxygenating, i.e. at least 48 hours prior to hospital discharge (discharge criterion) up to a maximum of 1 month after hospitalisation.
- Patient ≥ 18 years old
- Patient who has given free, informed and written consent
Exclusion
- Patient ≤ 18 years old
- CT Contraindication
- Pregnant or breastfeeding woman
Key Trial Info
Start Date :
June 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 24 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04483752
Start Date
June 8 2020
End Date
December 24 2022
Last Update
August 9 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Marie Lannelongue
Le Plessis-Robinson, France, 92350
2
Hôpital Saint Joseph
Paris, France, 75014
3
Institut Gustave Roussy (IGR)
Villejuif, France